Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 12 | 2012 | 173 | 1.190 |
Why?
|
| Anti-HIV Agents | 4 | 2011 | 195 | 0.990 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2012 | 73 | 0.980 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2021 | 18 | 0.860 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 255 | 0.720 |
Why?
|
| HIV Infections | 10 | 2012 | 961 | 0.680 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 424 | 0.600 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 660 | 0.500 |
Why?
|
| Virus Replication | 7 | 2012 | 284 | 0.430 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2021 | 481 | 0.430 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 35 | 0.410 |
Why?
|
| HIV | 1 | 2011 | 47 | 0.340 |
Why?
|
| HIV Protease Inhibitors | 4 | 2011 | 21 | 0.320 |
Why?
|
| Viral Load | 1 | 2010 | 154 | 0.310 |
Why?
|
| Viremia | 2 | 2008 | 51 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2011 | 1914 | 0.260 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2011 | 61 | 0.250 |
Why?
|
| HIV Fusion Inhibitors | 3 | 2011 | 3 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2011 | 21 | 0.240 |
Why?
|
| Models, Biological | 3 | 2011 | 1768 | 0.240 |
Why?
|
| Immune Tolerance | 3 | 2021 | 375 | 0.210 |
Why?
|
| Antiviral Agents | 4 | 2011 | 364 | 0.200 |
Why?
|
| Autoimmunity | 2 | 2021 | 189 | 0.190 |
Why?
|
| Integrase Inhibitors | 3 | 2011 | 3 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2021 | 37 | 0.170 |
Why?
|
| Virus Internalization | 2 | 2010 | 45 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1587 | 0.160 |
Why?
|
| HEK293 Cells | 2 | 2021 | 696 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 304 | 0.150 |
Why?
|
| Virus Latency | 2 | 2009 | 31 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 337 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 220 | 0.130 |
Why?
|
| Acyclovir | 2 | 2011 | 35 | 0.100 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 37 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3435 | 0.100 |
Why?
|
| Humans | 17 | 2021 | 93511 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1275 | 0.100 |
Why?
|
| Mice | 3 | 2021 | 12269 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2021 | 3502 | 0.090 |
Why?
|
| Animals | 5 | 2021 | 28155 | 0.090 |
Why?
|
| Mutation | 3 | 2021 | 4272 | 0.090 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 797 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 200 | 0.090 |
Why?
|
| Reverse Transcription | 2 | 2008 | 14 | 0.090 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2011 | 4 | 0.090 |
Why?
|
| Virion | 1 | 2011 | 61 | 0.090 |
Why?
|
| Herpesviridae | 1 | 2011 | 13 | 0.080 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 2 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 146 | 0.080 |
Why?
|
| Guanine | 2 | 2009 | 194 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2010 | 119 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 759 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 113 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2010 | 150 | 0.080 |
Why?
|
| Biological Factors | 1 | 2009 | 18 | 0.070 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2009 | 15 | 0.070 |
Why?
|
| Virus Activation | 1 | 2009 | 36 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 49 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2008 | 184 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2007 | 77 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2010 | 9098 | 0.060 |
Why?
|
| Phylogeny | 2 | 2008 | 1266 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1103 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2715 | 0.060 |
Why?
|
| Phenotype | 1 | 2011 | 2544 | 0.050 |
Why?
|
| Thymocytes | 1 | 2021 | 31 | 0.040 |
Why?
|
| Peripheral Tolerance | 1 | 2021 | 2 | 0.040 |
Why?
|
| Clonal Anergy | 1 | 2021 | 32 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2021 | 196 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 183 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 188 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 309 | 0.040 |
Why?
|
| Catalysis | 1 | 2017 | 216 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2017 | 363 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 422 | 0.030 |
Why?
|
| Immunity | 1 | 2017 | 153 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 438 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 2464 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1133 | 0.030 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1910 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 101 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 98 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2010 | 100 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 367 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 275 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 307 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 158 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 579 | 0.020 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2009 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1985 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 712 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 520 | 0.020 |
Why?
|
| Gene Library | 1 | 2009 | 126 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 470 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 587 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 374 | 0.020 |
Why?
|
| Lamivudine | 1 | 2007 | 13 | 0.020 |
Why?
|
| Zidovudine | 1 | 2007 | 13 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 219 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2007 | 13 | 0.020 |
Why?
|
| Virulence | 1 | 2008 | 273 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 253 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 73 | 0.020 |
Why?
|
| Peptides | 1 | 2010 | 656 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2007 | 47 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2012 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 2910 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1353 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 408 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 285 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2850 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 863 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 1953 | 0.010 |
Why?
|
| Male | 2 | 2021 | 44553 | 0.010 |
Why?
|
| Adult | 2 | 2011 | 27918 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5410 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 27569 | 0.000 |
Why?
|